Intra-articular biomaterials such as stiffness-tunable hydrogels and stimuli-responsive nanocarriers are being experimentally explored to modulate the glycated, inflamed, and mechanically altered joint microenvironment in diabetes-related osteoarthritis, but their efficacy in humans has not been established.

High blood sugar causes proteins in joint cartilage to stick together abnormally, making the tissue stiff and brittle. This stiffness tricks cartilage cells into thinking they are under constant mechanical stress, which turns on harmful signaling pathways. At the same time, the stuck proteins bind to a receptor on the cells, triggering inflammation. Together, these two signals turn on a master switch called NF-κB that activates enzymes that break down cartilage and block repair mechanisms. The stiff environment also shuts down a protective system that normally keeps inflammation in check, making the damage worse and harder to reverse.